Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v10-FR | Version v5-FR | |
---|---|---|
Language | French | French |
Date Updated | 2021-10-08 | 2021-06-04 |
Drug Identification Number | 02244475 | 02244475 |
Brand name | DIPYRIDAMOLE INJECTION, USP | DIPYRIDAMOLE INJECTION, USP |
Common or Proper name | Dipyridamole Injection, USP 5 mg/mL SD Vial 10 mL | Dipyridamole Injection, USP 5 mg/mL SD Vial 10 mL |
Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
Ingredients | DIPYRIDAMOLE | DIPYRIDAMOLE |
Strength(s) | 5MG | 5MG |
Dosage form(s) | LIQUID | LIQUID |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 10 mL | 10 mL |
ATC code | B01AC | B01AC |
ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-04-30 | 2021-04-30 |
Actual start date | ||
Estimated end date | 2021-10-01 | 2021-08-31 |
Actual end date | 2021-10-01 | |
Shortage status | Resolved | Actual shortage |
Tier 3 Status | No | No |
Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to further production delays we will be extending the backorder on our on our Dipyridamole Injection, USP 5 mg/mL 10 mL Vial until August 31st, 2021. Glenwood is an alternate supplier of Dipyridamole Injection and have been informed of our impending supply interruption. | |
Health Canada comments |